Item Type | Name |
Academic Article
|
Altered platelet function in diabetes mellitus.
|
Academic Article
|
Pathogenesis of atherosclerosis in diabetes mellitus.
|
Academic Article
|
Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.
|
Academic Article
|
A review of the development of large-vessel disease in diabetes mellitus.
|
Academic Article
|
Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients.
|
Academic Article
|
Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients.
|
Academic Article
|
Insulin and arachidonic acid metabolism in diabetes mellitus.
|
Academic Article
|
Do platelets have anything to do with diabetic microvascular disease?
|
Academic Article
|
New concepts about the pathogenesis of atherosclerosis in diabetes mellitus.
|
Academic Article
|
Platelet function in diabetes mellitus.
|
Academic Article
|
Increased platelet arachidonic acid metabolism in diabetes mellitus.
|
Academic Article
|
Platelet plasminogen activator inhibitor 1 in patients with type II diabetes.
|
Academic Article
|
Platelet adhesion and aggregation in diabetes mellitus.
|
Concept
|
Platelet Function Tests
|
Concept
|
Platelet Factor 4
|
Concept
|
Blood Platelets
|
Concept
|
Platelet Adhesiveness
|
Concept
|
Platelet Activation
|
Concept
|
Platelet Aggregation Inhibitors
|
Concept
|
Platelet Aggregation
|
Concept
|
Platelet Activating Factor
|
Academic Article
|
The effect of oral glucose on von Willebrand factor activity in normal and diabetic subjects.
|
Academic Article
|
Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease.
|
Academic Article
|
Increased platelet aggregation in early diabetus mellitus.
|
Academic Article
|
Inhibition of labile aggregation-stimulating substance (LASS) and platelet aggregation in diabetes mellitus.
|
Academic Article
|
Antiplatelet drugs and prevention of macrovascular disease in diabetes mellitus.
|
Academic Article
|
Clinical trials of antiplatelet agents in diabetes mellitus: rationale and results.
|
Academic Article
|
Pathophysiology of vascular disease in diabetes: effects of gliclazide.
|
Academic Article
|
Antiplatelet agents and diabetic vascular disease.
|
Academic Article
|
Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates.
|
Academic Article
|
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
|
Academic Article
|
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics.
|
Academic Article
|
Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation.
|
Academic Article
|
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics.
|
Academic Article
|
Atherosclerosis in diabetes mellitus.
|
Academic Article
|
Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients.
|
Academic Article
|
Aspirin therapy in diabetes mellitus.
|
Academic Article
|
Aspirin therapy in diabetes.
|
Academic Article
|
Multifactorial aspects of the treatment of the type II diabetic patient.
|
Academic Article
|
The platelet in diabetes: focus on prevention of ischemic events.
|
Academic Article
|
Aspirin for primary prevention of cardiovascular events in diabetes.
|
Academic Article
|
Aspirin therapy in diabetes.
|
Academic Article
|
Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus.
|
Academic Article
|
Aspirin for the primary prevention of cardiovascular events.
|
Academic Article
|
An appraisal of aspirin therapy in diabetes.
|
Academic Article
|
Does aspirin use reduce cardiovascular risk in diabetes?
|
Academic Article
|
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.
|
Academic Article
|
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.
|
Academic Article
|
Aspirin for primary prevention of cardiovascular events in people with diabetes.
|
Academic Article
|
Aspirin and risk of hemorrhagic stroke.
|
Academic Article
|
Treatment for the procoagulant state in type 2 diabetes.
|